Skip to main content

CAR T therapy Archives

Team’s findings show glutamine metabolism affects T cell signaling

Nov. 1, 2018—The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered.

Read more


Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR T therapy

Oct. 25, 2017—Vanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.

Read more


Recent Stories from VUMC News and Communications Publications

Our amazing skin

Vanderbilt Medicine

Our amazing skin

Biology and the beat

Vanderbilt Medicine

Biology and the beat

Community care

Vanderbilt Nurse

Community care

Survive and thrive

Hope

Survive and thrive

more